Abstract 5714
Background
Addition of D to ADT increased overall survival in high volume disease mHSPC. Nevertheless, there is a lack of information about the management after disease progression and predictive factors of efficacy for subsequent therapies are unknown.
Methods
Retrospective analysis of 163 mHSPC patients (pt) treated with D in 23 Spanish Centers from July 2014 to April 2018. Objectives of the study are: describe baseline and progression characteristics, treatment choices and efficacy outcomes of subsequent therapies based on pretreatment features.
Results
After a median follow up of 18.04 months (m), 93 pt (57.1%) developed CRPC. Median time to CRPC was 15.97 m (CI 95%: 10.97 m – 28.16 m). 80 pt received subsequent treatment after progression: 23 (28.8%) received chemotherapy (CT) (3 D, 17 cabazitaxel, 3 carboplatin-etoposide), 52 (65%) androgen receptor axis-targeted agents (31 enzalutamide, 21 abiraterone) and 5 radium-223. Baseline characteristics of pt at CRPC disease were: median age: 67.1 year; median PSA doubling time (PSADT): 2 m, and median PSA, Hemoglobin (Hb), LDH and alkaline phosphatase (alk-P) was 20.3 ng/mL, 12.95 g/dL, 326 UI/mL and 144 UI/mL, respectively. 26.4% of pt had visceral progression. Median progression free survival (PFS) of pt in first-line treatment for mCRPC was 6.93 m (CI95%: 3.58-10.02). In univariate analysis, hormonal therapy showed a significant longer PFS compared to CT (7.49 m vs 6.27 m; HR 0.55; p 0.048), but no association was found after adjustment by other prognostic characteristics (HR 0.77; p 0.79). Although no significant association was observed in multivariate analysis, pt with more aggressive clinical characteristics achieved a longer PFS with CT (Table).Table: 823P
PFS at first-line treatment of mCRPC
| HT (m) | CT (m) | p | |
|---|---|---|---|
| PSADT < 3 m PSADT > = 3 m | 4.46 9.39 | 6.27 3.59 | 0.6 0.07 |
| Visceral PD Non Visceral PD | 4.33 5.95 | 5.59 3.54 | 0.59 0.12 |
| LDH H LDH L | 4.34 12.0 | 5.59 8.21 | 0.29 0.3 |
| Hb H Hb L | NR 4.0 | 5.58 6.27 | 0.03 0.63 |
| alk-P H alk-P L | 3.81 11.99 | 6.93 5.52 | 0.94 0.03 |
| PSA H PSA L | 3.81 8.54 | 5.52 5.58 | 0.35 0.14 |
Conclusions
Baseline characteristics at CRPC disease could help us to identify the best therapy option for pt pretreated with D + ADT in mHSPC. Our analyses suggest that CT could benefit pt with more aggressive clinical features.
Clinical trial identification
Legal entity responsible for the study
Pablo Gajate Borau.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract